scholarly journals Using an Artificial Neural Network to Predict Coronary Microvascular Obstruction (No-Reflow Phenomenon) during Percutaneous Coronary Interventions in Patients with Myocardial Infarction

2021 ◽  
Vol 13 (6) ◽  
pp. 6
Author(s):  
A.A. Frolov ◽  
I.G. Pochinka ◽  
B.E. Shakhov ◽  
A.S. Mukhin ◽  
I.A. Frolov ◽  
...  
Keyword(s):  
Neural Network ◽  
Myocardial Infarction ◽  
Artificial Neural Network ◽  
Microvascular Obstruction ◽  
Percutaneous Coronary Interventions ◽  
No Reflow ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
No Reflow Phenomenon ◽  
Artificial Neural

scholarly journals Coronary microvascular obstruction (the no-reflow phenomenon) during percutaneous coronary interventions in patients with myocardial infarction

2020 ◽  
Vol 24 (1) ◽  
pp. 18
Author(s):  
A. A. Frolov ◽  
I. G. Pochinka ◽  
B. E. Shahov ◽  
E. G. Sharabrin ◽  
K. V. Kuzymichev
Keyword(s):  
Myocardial Infarction ◽  
Conflict Of Interest ◽  
Microvascular Obstruction ◽  
Negative Impact ◽  
Relevant Literature ◽  
Percutaneous Coronary Interventions ◽  
No Reflow ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
No Reflow Phenomenon

<p>Coronary microvascular obstruction (the no-reflow phenomenon) after percutaneous coronary interventions in diagnosed with myocardial infarction has a significant negative impact on both the short-term and long-term prognosis. The mechanisms underlying this disorder are heterogeneous and complex, and as such it is difficult to devise effective treatments and/or to predict specific outcomes. Modern therapeutic approaches have indirect cardioprotective effects and certainly reduce the risk of no-reflow. However, attempts to create a drug or method that fundamentally improve the prognosis in patients with coronary microvascular obstruction have been unsuccessful. Thus, the problem of myocardial reperfusion damage has not been solved and further study will be necessary to provide support for the search for new therapeutic modalities. The purpose of this review is to provide an analysis of relevant literature that focuses on the aetiology, pathogenesis, diagnosis, prognosis and treatment of the coronary microvascular obstruction during and after percutaneous coronary interventions in patients diagnosed with myocardial infarction. We searched using the Medline (PubMed), RSCI (eLIBRARY), Embase and Google Scholar databases for all relevant literature pertaining to this subject.</p><p>Received 13 January 2020. Accepted 11 February 2020.</p><p><strong>Funding:</strong> The study did not have sponsorship. </p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p>

scholarly journals Clinical and Procedural Predictors of No-Reflow Phenomenon After Primary Percutaneous Coronary Interventions

2008 ◽  
Vol 72 (5) ◽  
pp. 716-721 ◽  
Author(s):  
Cevat Kirma ◽  
Akin Izgi ◽  
Cihan Dundar ◽  
Ali Cevat Tanalp ◽  
Vecih Oduncu ◽  
...  
Keyword(s):  
Percutaneous Coronary Interventions ◽  
No Reflow ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
No Reflow Phenomenon

scholarly journals Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome

2020 ◽  
Author(s):  
Nian-Peng Song ◽  
Xiao-Wen Zhen ◽  
Liu-dong Li ◽  
Lin Zhong ◽  
Hua Wang ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Platelet Activation ◽  
Negative Impact ◽  
Chinese Patients ◽  
Percutaneous Coronary Interventions ◽  
Coronary Syndrome ◽  
No Reflow ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
No Reflow Phenomenon

Abstract Background No-reflow occurs in 3–4% of all percutaneous coronary interventions and has a strong negative impact on clinical outcomes of acute coronary syndrome. Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. But the association of plasma calprotectin with platelet activation and no-reflow phenomenon in acute coronary syndrome is not clear. Methods In this study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with acute coronary syndrome who had undergone percutaneous coronary interventions were recruited consecutively, aged from 30 to 88 years. The coronary angiography and percutaneous coronary intervention procedures were performed and angiographic no-reflow was defined as a thrombolysis in myocardial infarction scores grade less than 3. Blood samples were collected immediately at admission for detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and for the prediction value of plasma calprotectin for no-reflow.Results In this study, we have demonstrated that acute coronary syndrome patients with higher plasma calprotectin had an elevated level of platelet activation and a higher incidence of no-reflow. Plasma calprotectin level was independently associated with platelet activation and no-reflow in patients with acute coronary syndrome. Despite that platelet activation biomarker platelet–monocyte aggregate was associated with no-flow, only plasma calprotectin and serum low density lipoprotein cholesterol acted as independent predictors of no-reflow in patients with acute coronary syndrome.Conclusion Plasma calprotectin was associated with platelet activation and may act as an early prediction biomarker of no-reflow in patients with acute coronary syndrome.

Sign in / Sign up

Export Citation Format

Share Document